1
|
Pluteanu F, Boknik P, Heinick A, König C, Müller FU, Weidlich A, Kirchhefer U. Activation of PKC results in improved contractile effects and Ca cycling by inhibition of PP2A-B56α. Am J Physiol Heart Circ Physiol 2022; 322:H427-H441. [PMID: 35119335 DOI: 10.1152/ajpheart.00539.2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Protein phosphatase 2A (PP2A) represents a heterotrimer that is responsible for the dephosphorylation of important regulatory myocardial proteins. The present study was aimed to test whether the phosphorylation of PP2A-B56α at Ser41 by PKC is involved in the regulation of myocyte Ca2+ cycling and contraction. For this purpose, heart preparations of wild-type (WT) and transgenic mice overexpressing the non-phosphorylatable S41A mutant form (TG) were stimulated by administration of the direct PKC activator phorbol 12-myristate 13-acetate (PMA), and functional effects were studied. PKC activation was accompanied by the inhibition of PP2A activity in WT cardiomyocytes, whereas this effect was absent in TG. Consistently, the increase in the sarcomere length shortening and the peak amplitude of Ca2+ transients after PMA administration in WT cardiomyocytes was attenuated in TG. However, the co-stimulation with 1 µM isoprenaline was able to offset these functional deficits. Moreover, TG hearts did not show an increase in the phosphorylation of the myosin-binding protein C after administration of PMA but was detected in corresponding WT. PMA modulated voltage-dependent activation of the L-type Ca2+ channel (LTCC) differently in the two genotypes, shifting V1/2a by +1.5 mV in TG and by 2.4 mV in WT. In the presence of PMA, ICaL inactivation remained unchanged in TG, whereas it was slower in corresponding WT. Our data suggest that PKC-activated enhancement of myocyte contraction and intracellular Ca2+ signaling is mediated by phosphorylation of B56α at Ser41, leading to a decrease in PP2A activity.
Collapse
Affiliation(s)
- Florentina Pluteanu
- Department of Anatomy, Animal Physiology and Biophysics, University of Bucharest, Bucharest, Romania
| | - Peter Boknik
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | - Alexander Heinick
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | - Christiane König
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | - Frank U Müller
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | - Adam Weidlich
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | - Uwe Kirchhefer
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| |
Collapse
|
2
|
Muslimova EF, Rebrova TY, Kondratieva DS, Afanasiev SA. Role of Phospholamban (PLN), Triadin (TRDN), and Junctin (ASPH) Genes in the Development of Myocardial Contractile Dysfunction. RUSS J GENET+ 2021. [DOI: 10.1134/s1022795421050069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
3
|
Berton MP, de Antunes Lemos MV, Seleguim Chud TC, Bonvino Stafuzza N, Kluska S, Amorim ST, Silva Ferlin Lopes L, Cravo Pereira AS, Bickhart D, Liu G, Galvão de Albuquerque L, Baldi F. Genome-wide association study between copy number variation regions and carcass- and meat-quality traits in Nellore cattle. ANIMAL PRODUCTION SCIENCE 2021. [DOI: 10.1071/an20275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Context
Indicine breeds are the main source of beef products in tropical and subtropical regions. However, genetic improvement for carcass- and meat-quality traits in zebu cattle have been limited and genomics studies concerning structural variations that influence these traits are essential.
Aim
The aim of this study was to perform a genome-wide association study between copy number variation regions (CNVRs) and carcass- and meat quality-traits in Nellore cattle.
Methods
In total, 3794 animals, males and females included, were genotyped using a 777962 single-nucleotide polymorphism platform of BovineHD BeadChip (777k; Illumina Inc.). Of these, 1751 Nellore bulls were slaughtered at 24 months of age for further carcass beef analysis. The following traits were studied: beef tenderness, marbling, rib-eye area, backfat thickness and meat colour (lightness, redness and yellowness). The CNV detection was conducted through PennCNV software. The association analyses were performed using CNVRuler software.
Key results
Several identified genomic regions were linked to quantitative trait loci associated with fat deposition (FABP7) and lipid metabolism (PPARA; PLA2 family; BCHE), extracellular matrix (INS; COL10A1), contraction (SLC34A3; TRDN) and muscle development (CAPZP). The gene-enrichment analyses highlighted biological mechanisms directly related to the metabolism and synthesis of lipids and fatty acids.
Conclusions
The large number of potential candidate genes identified within the CNVRs, as well as the functions and pathways identified, should help better elucidate the genetic mechanisms involved in the expression of beef and carcass traits in Nellore cattle. Several CNVRs harboured genes that might have a functional impact to improve the beef and carcass traits.
Implications
The results obtained contribute to upgrade the sensorial and organoleptic attributes of Nellore cattle and make feasible the genetic improvement of carcass- and meat-quality traits.
Collapse
|
4
|
Ihara K, Sasano T, Hiraoka Y, Togo-Ohno M, Soejima Y, Sawabe M, Tsuchiya M, Ogawa H, Furukawa T, Kuroyanagi H. A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fibrillation in mice. Sci Rep 2020; 10:17894. [PMID: 33110103 PMCID: PMC7591520 DOI: 10.1038/s41598-020-74800-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 10/06/2020] [Indexed: 02/07/2023] Open
Abstract
Dilated cardiomyopathy (DCM) is a fatal heart disease characterized by left ventricular dilatation and cardiac dysfunction. Recent genetic studies on DCM have identified causative mutations in over 60 genes, including RBM20, which encodes a regulator of heart-specific splicing. DCM patients with RBM20 mutations have been reported to present with more severe cardiac phenotypes, including impaired cardiac function, atrial fibrillation (AF), and ventricular arrhythmias leading to sudden cardiac death, compared to those with mutations in the other genes. An RSRSP stretch of RBM20, a hotspot of missense mutations found in patients with idiopathic DCM, functions as a crucial part of its nuclear localization signals. However, the relationship between mutations in the RSRSP stretch and cardiac phenotypes has never been assessed in an animal model. Here, we show that Rbm20 mutant mice harboring a missense mutation S637A in the RSRSP stretch, mimicking that in a DCM patient, demonstrated severe cardiac dysfunction and spontaneous AF and ventricular arrhythmias mimicking the clinical state in patients. In contrast, Rbm20 mutant mice with frame-shifting deletion demonstrated less severe phenotypes, although loss of RBM20-dependent alternative splicing was indistinguishable. RBM20S637A protein cannot be localized to the nuclear speckles, but accumulated in cytoplasmic, perinuclear granule-like structures in cardiomyocytes, which might contribute to the more severe cardiac phenotypes.
Collapse
Affiliation(s)
- Kensuke Ihara
- Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan. .,Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan.
| | - Tetsuo Sasano
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Yuichi Hiraoka
- Laboratory of Molecular Neuroscience, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Marina Togo-Ohno
- Laboratory of Gene Expression, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Yurie Soejima
- Department of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Motoji Sawabe
- Department of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Megumi Tsuchiya
- Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Hidesato Ogawa
- Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Tetsushi Furukawa
- Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan
| | - Hidehito Kuroyanagi
- Laboratory of Gene Expression, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8510, Japan.
| |
Collapse
|
5
|
Boknik P, Drzewiecki K, Eskandar J, Gergs U, Hofmann B, Treede H, Grote-Wessels S, Fabritz L, Kirchhof P, Fortmüller L, Müller FU, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J. Evidence for Arrhythmogenic Effects of A 2A-Adenosine Receptors. Front Pharmacol 2019; 10:1051. [PMID: 31619997 PMCID: PMC6759833 DOI: 10.3389/fphar.2019.01051] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 08/20/2019] [Indexed: 12/26/2022] Open
Abstract
Adenosine can be released from the heart and may stimulate four different cardiac adenosine receptors. A receptor subtype that couples to the generation of cyclic adenosine monophosphate (cAMP) is the A2A-adenosine receptor (A2A-AR). To better understand its role in cardiac function, we studied mechanical and electrophysiological effects in transgenic mice that overexpress the human A2A-AR in cardiomyocytes (A2A-TG). We used isolated preparations from the left atrium, the right atrium, isolated perfused hearts with surface electrocardiogram (ECG) recording, and surface body ECG recordings of living mice. The hypothesized arrhythmogenic effects of transgenicity per se and A2A-AR stimulation were studied. We noted an increase in the incidence of supraventricular and ventricular arrhythmias under these conditions in A2A-TG. Moreover, we noted that the A2A-AR agonist CGS 21680 exerted positive inotropic effect in isolated human electrically driven (1 Hz) right atrial trabeculae carneae. We conclude that A2A-ARs are functional not only in A2A-TG but also in isolated human atrial preparations. A2A-ARs in A2A-TG per se and their stimulation can lead to cardiac arrhythmias not only in isolated cardiac preparations from A2A-TG but also in living A2A-TG.
Collapse
Affiliation(s)
- Peter Boknik
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Katharina Drzewiecki
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - John Eskandar
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Ulrich Gergs
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| | - Britt Hofmann
- Klinik für Herzchirurgie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| | - Hendrik Treede
- Klinik für Herzchirurgie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| | - Stephanie Grote-Wessels
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Larissa Fabritz
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.,University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Paulus Kirchhof
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.,University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.,Sandwell and West Birmingham Hospital NHS Trust, Birmingham, United Kingdom
| | - Lisa Fortmüller
- Institute for Human Genetics, Genetic epidemiology, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Frank Ulrich Müller
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Wilhelm Schmitz
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | | | - Uwe Kirchhefer
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Joachim Neumann
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| |
Collapse
|
6
|
Kirchhefer U, Hammer E, Heinick A, Herpertz T, Isensee G, Müller FU, Neumann J, Schulte K, Seidl MD, Boknik P, Schulte JS. Chronic β-adrenergic stimulation reverses depressed Ca handling in mice overexpressing inhibitor-2 of protein phosphatase 1. J Mol Cell Cardiol 2018; 125:195-204. [PMID: 30389400 DOI: 10.1016/j.yjmcc.2018.10.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 10/26/2018] [Indexed: 11/16/2022]
Abstract
RATIONALE A higher expression/activity of type 1 serine/threonine protein phosphatase 1 (PP1) may contribute to dephosphorylation of cardiac regulatory proteins triggering the development of heart failure. OBJECTIVE Here, we tested the putatively protective effects of PP1 inhibitor-2 (I2) overexpression using a heart failure model induced by chronic β-adrenergic stimulation. METHODS AND RESULTS Transgenic (TG) and wild-type (WT) mice were subjected to isoprenaline (ISO) or isotonic NaCl solution supplied via osmotic minipumps for 7 days. I2 overexpression was associated with a depressed PP1 activity. Basal contractility was unchanged in catheterized mice and isolated cardiomyocytes between TGNaCl and WTNaCl. TGISO mice exhibited more fibrosis and a higher expression of hypertrophy marker proteins as compared to WTISO. After acute administration of ISO, the contractile response was accompanied by a higher sensitivity in TGISO as compared to WTISO. In contrast to basal contractility, the peak amplitude of [Ca]i and SR Ca load were reduced in TGNaCl as compared to WTNaCl. These effects were normalized to WT levels after chronic ISO stimulation. Cardiomyocyte relaxation and [Ca]i decay kinetics were hastened in TGISO as compared to WTISO, which can be explained by a higher phospholamban phosphorylation at Ser16. Chronic catecholamine stimulation was followed by an enhanced expression of GSK3β, whereas the phosphorylation at Ser9 was lower in TG as compared to the corresponding WT group. This resulted in a higher I2 phosphorylation that may reactivate PP1. CONCLUSION Our findings suggest that the basal desensitization of β-adrenergic signaling and the depressed Ca handling in TG by inhibition of PP1 is restored by a GSK3β-dependent phosphorylation of I2.
Collapse
Affiliation(s)
- Uwe Kirchhefer
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany.
| | - Elke Hammer
- Interfakultäres Institut für Genetik und Funktionelle Genomforschung, Universitätsmedizin Greifswald, Germany
| | - Alexander Heinick
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Thomas Herpertz
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Gunnar Isensee
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Frank U Müller
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Joachim Neumann
- Institute of Pharmacology and Toxicology, Faculty of Medicine, Martin-Luther-University, Halle, Germany
| | - Kirsten Schulte
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Matthias D Seidl
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Peter Boknik
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| | - Jan S Schulte
- Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, Münster, Germany
| |
Collapse
|
7
|
Successful overexpression of wild-type inhibitor-2 of PP1 in cardiovascular cells. Naunyn Schmiedebergs Arch Pharmacol 2018; 391:859-873. [PMID: 29797049 DOI: 10.1007/s00210-018-1515-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Accepted: 05/13/2018] [Indexed: 01/16/2023]
Abstract
About half of the cardiac serine/threonine phosphatase activity is due to the activity of protein phosphatase type 1 (PP1). The activity of PP1 can be inhibited by an endogenous protein for which the expression inhibitor-2 (I-2) has been coined. We have previously described a transgenic mouse overexpressing a truncated form of I-2. Here, we have described and initially characterized several founders that overexpress the non-truncated (i.e., full length) I-2 in the mouse heart (TG) and compared them with non-transgenic littermates (WT). The founder with the highest overexpression of I-2 displayed under basal conditions no difference in contractile parameters (heart rate, developed tension, and its first derivate) compared to WT. The relative level of PP1 inhibition was similar in mice overexpressing the non-truncated as well as the truncated form of I-2. For comparison, we overexpressed I-2 by an adenoviral system in several cell lines (myocytes from a tumor-derived cell line (H9C2), neonatal rat cardiomyocytes, smooth muscle cells from rat aorta (A7R5)). We noted gene dosage-dependent staining for I-2 protein in infected cells together with reduced PP1 activity. Finally, I-2 expression in neonatal rat cardiomyocytes led to an increase of Ca2+ transients by about 60%. In summary, we achieved immunologically confirmed overexpression of wild-type I-2 in cardiovascular cells which was biochemically able to inhibit PP1 in the whole heart (using I-2 transgenic mice) as well as in isolated cells including cardiomyocytes (using I-2 coding virus) indirectly underscoring the importance of PP1 for cardiovascular function.
Collapse
|
8
|
Gergs U, Rothkirch D, Hofmann B, Treede H, Robaye B, Simm A, Müller CE, Neumann J. Mechanism underlying the contractile activity of UTP in the mammalian heart. Eur J Pharmacol 2018; 830:47-58. [PMID: 29673908 DOI: 10.1016/j.ejphar.2018.04.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Revised: 04/10/2018] [Accepted: 04/13/2018] [Indexed: 12/19/2022]
Abstract
We previously reported that uridine 5'-triphosphate (UTP), a pyrimidine nucleoside triphosphate produced a concentration- and time-dependent increase in the contraction force in isolated right atrial preparations from patients undergoing cardiac bypass surgery due to angina pectoris. The stimulation of the force of contraction was sustained rather than transient. In the present study, we tried to elucidate the underlying receptor and signal transduction for this effect of UTP. Therefore, we measured the effect of UTP on force of contraction, phosphorylation of p38 and ERK1/2, in human atrial preparations, atrial preparations from genetically modified mice, cardiomyocytes from adult mice and cardiomyocytes from neonatal rats. UTP exerted a positive inotropic effect in isolated electrically driven left atrial preparations from wild-type (WT) mice and P2Y2-, P2Y4- and P2Y6-receptor knockout mice. Therefore, we concluded that these P2Y receptors did not mediate the inotropic effects of UTP in atrial preparations from mice. However, UTP (like ATP) increased the phosphorylation states of p38 and ERK1/2 in neonatal rat cardiomyocytes, adult mouse cardiomyocytes and human atrial tissue in vitro. U0126, a MEK 1/2- signal cascade inhibitor, attenuated this phosphorylation and the positive inotropic effects of UTP in murine and human atrial preparations. We suggest that presently unknown receptors mediate the positive inotropic effect of UTP in murine and human atria. We hypothesize that UTP stimulates inotropy via p38 or ERK1/2 phosphorylation. We speculate that UTP may be a valuable target in the development of new drugs aimed at treating human systolic heart failure.
Collapse
Affiliation(s)
- Ulrich Gergs
- Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany
| | - Daniel Rothkirch
- Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany
| | - Britt Hofmann
- Cardiac Surgery, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany
| | - Hendrik Treede
- Cardiac Surgery, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Andreas Simm
- Cardiac Surgery, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany
| | - Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, Pharmaceutical Sciences Bonn (PSB), University of Bonn, Germany
| | - Joachim Neumann
- Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany.
| |
Collapse
|
9
|
Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J. Phenotyping of Mice with Heart Specific Overexpression of A 2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A 2A-Adenosine Receptors. Front Pharmacol 2018; 9:13. [PMID: 29403384 PMCID: PMC5786519 DOI: 10.3389/fphar.2018.00013] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Accepted: 01/05/2018] [Indexed: 11/28/2022] Open
Abstract
Background: Adenosine can be produced in the heart and acts on cardiac adenosine receptors. One of these receptors is the A2A-adenosine receptor (A2A-AR). Methods and Results: To better understand its role in cardiac function, we generated and characterized mice (A2A-TG) which overexpress the human A2A-AR in cardiomyocytes. In isolated atrial preparations from A2A-TG but not from WT, CGS 21680, an A2A-AR agonist, exerted positive inotropic and chronotropic effects. In ventricular preparations from A2A-TG but not WT, CGS 21680 increased the cAMP content and the phosphorylation state of phospholamban and of the inhibitory subunit of troponin in A2A-TG but not WT. Protein expression of phospholamban, SERCA, triadin, and junctin was unchanged in A2A-TG compared to WT. Protein expression of the α-subunit of the stimulatory G-protein was lower in A2A-TG than in WT but expression of the α-subunit of the inhibitory G-protein was higher in A2A-TG than in WT. While basal hemodynamic parameters like left intraventricular pressure and echocardiographic parameters like the systolic diameter of the interventricular septum were higher in A2A-TG than in WT, after β-adrenergic stimulation these differences disappeared. Interestingly, A2A-TG hearts sustained global ischemia better than WT. Conclusion: We have successfully generated transgenic mice with cardiospecific overexpression of a functional A2A-AR. This receptor is able to increase cardiac function per se and after receptor stimulation. It is speculated that this receptor may be useful to sustain contractility in failing human hearts and upon ischemia and reperfusion.
Collapse
Affiliation(s)
- Peter Boknik
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Katharina Drzewiecki
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - John Eskandar
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Ulrich Gergs
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| | - Stephanie Grote-Wessels
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Larissa Fabritz
- Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Paulus Kirchhof
- Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Frank U Müller
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Frank Stümpel
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Wilhelm Schmitz
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | | | - Uwe Kirchhefer
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster, Germany
| | - Joachim Neumann
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
| |
Collapse
|
10
|
Zhang L, Salgado-Somoza A, Vausort M, Leszek P, Devaux Y. A heart-enriched antisense long non-coding RNA regulates the balance between cardiac and skeletal muscle triadin. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2017; 1865:247-258. [PMID: 29126880 DOI: 10.1016/j.bbamcr.2017.11.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 11/02/2017] [Accepted: 11/03/2017] [Indexed: 12/20/2022]
Abstract
Non-coding RNAs play major roles in cardiac pathophysiology. Recent studies reported that long non-coding RNAs (lncRNAs) are dysregulated in the failing heart, but how they contribute to heart failure development is unclear. In this study, we aimed to identify heart-enriched lncRNAs and investigate their regulation and function in the failing heart. RESULTS Analysis of a RNA-seq dataset of 15 Caucasian tissues allowed the identification of 415 heart-enriched lncRNAs. Fifty-three lncRNAs were located on the genome in close vicinity to protein-coding genes associated with cardiac function and disease. Analysis of a second RNA-seq dataset of 16 failing human hearts highlighted one lncRNA which we arbitrarily named TRDN-AS due to its localisation in the antisense position of the gene encoding triadin (TRDN). Expression of TRDN-AS and cardiac TRDN was up-regulated in biopsies from failing human hearts compared to control hearts. In failing hearts, TRDN-AS was positively correlated with a cardiac isoform of TRDN and negatively correlated with a skeletal muscle isoform of TRDN. A murine homolog of human TRDN-AS was identified and found to be enriched in the heart and localised in the nuclear compartment of cardiomyocytes. Trdn-AS expression as well as the ratio between cardiac and skeletal muscle isoforms were down-regulated after experimental myocardial infarction. In murine cardiomyocytes, activation of Trdn-AS transcription with the CRISPR/dCas9-VPR system enhanced the ratio between cardiac and skeletal isoforms of Trdn. CONCLUSION The lncRNA TRDN-AS regulates the balance between cardiac and skeletal isoforms of triadin. This finding may have implications for the treatment of heart failure.
Collapse
Affiliation(s)
- Lu Zhang
- Cardiovascular Research Unit, Luxembourg Health Institute, Luxembourg
| | | | - Melanie Vausort
- Cardiovascular Research Unit, Luxembourg Health Institute, Luxembourg
| | - Przemyslaw Leszek
- Heart Failure and Transplantology Department, Institute of Cardiology, Warsaw, Poland
| | - Yvan Devaux
- Cardiovascular Research Unit, Luxembourg Health Institute, Luxembourg.
| | | |
Collapse
|
11
|
Desensitization of the human 5-HT 4 receptor in isolated atria of transgenic mice. Naunyn Schmiedebergs Arch Pharmacol 2017; 390:987-996. [PMID: 28689254 DOI: 10.1007/s00210-017-1403-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Accepted: 06/28/2017] [Indexed: 10/19/2022]
Abstract
In the human cardiovascular system, serotonin (5-HT) exerts positive inotropic and chronotropic effects mediated by 5-HT4 receptors. Moreover, 5-HT4 receptor stimulation can cause arrhythmias in the human heart. Response to 5-HT can fade due to desensitization of the receptor system and/or activation of phosphodiesterases. In this study, we investigated a potential desensitization of the human 5-HT4(a) receptor expressed in the mouse heart. Therefore, we have used atrial preparations of transgenic (TG) mice with cardiac myocyte-specific overexpression of the human 5-HT4(a) receptor and their non-transgenic littermates (WT). Homologous (by 5-HT) and potentially heterologous (by isoprenaline) desensitization of the 5-HT4 receptor was investigated in atria of TG mice. 5-HT increased force of contraction in isolated electrically paced left atria and beating rate in spontaneously beating right atria only in preparations from TG but not from WT. Pre-treatment of isolated atria with high concentrations (10-600 μM) of 5-HT for 60 min attenuated the positive inotropic effects and the positive chronotropic effects of 5-HT in TG atria. Several inhibitors of desensitization including Zn2+, sucrose, and paroxetine were tested. Whereas sucrose was without any effect and Zn2+ only was partially effective, paroxetine was able to inhibit desensitization favoring at least in part a G-protein receptor-coupled kinase-mediated mechanism of 5-HT4 receptor desensitization in the TG mouse heart. In addition, desensitization of ventricular 5-HT4 receptors was noted in isolated perfused hearts (Langendorff preparations) from TG mice. In summary, we show homologous desensitization of the 5-HT4 receptor in the heart of a transgenic mouse model possibly dependent on active G-protein receptor-coupled kinase. The exact mechanism and a potentially heterologous desensitization have to be elucidated by further investigations.
Collapse
|
12
|
Xia J, Qi X, Wu Y, Zhu B, Xu L, Zhang L, Gao X, Chen Y, Li J, Gao H. Genome-wide association study identifies loci and candidate genes for meat quality traits in Simmental beef cattle. Mamm Genome 2016; 27:246-55. [PMID: 27126640 DOI: 10.1007/s00335-016-9635-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 04/11/2016] [Indexed: 12/13/2022]
Abstract
Improving meat quality is the best way to enhance profitability and strengthen competitiveness in beef industry. Identification of genetic variants that control beef quality traits can help breeders design optimal breeding programs to achieve this goal. We carried out a genome-wide association study for meat quality traits in 1141 Simmental cattle using the Illumina Bovine HD 770K SNP array to identify the candidate genes and genomic regions associated with meat quality traits for beef cattle, including fat color, meat color, marbling score, longissimus muscle area, and shear force. In our study, we identified twenty significant single-nucleotide polymorphisms (SNPs) (p < 1.47 × 10(-6)) associated with these five meat quality traits. Notably, we observed several SNPs were in or near eleven genes which have been reported previously, including TMEM236, SORL1, TRDN, S100A10, AP2S1, KCTD16, LOC506594, DHX15, LAMA4, PREX1, and BRINP3. We identified a haplotype block on BTA13 containing five significant SNPs associated with fat color trait. We also found one of 19 SNPs was associated with multiple traits (shear force and longissimus muscle area) on BTA7. Our results offer valuable insights to further explore the potential mechanism of meat quality traits in Simmental beef cattle.
Collapse
Affiliation(s)
- Jiangwei Xia
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Xin Qi
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Yang Wu
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Bo Zhu
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Lingyang Xu
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Lupei Zhang
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Xue Gao
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Yan Chen
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China
| | - Junya Li
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China.
| | - Huijiang Gao
- Institute of Animal Science, Chinese Academy of Agricultural Science, No.2 Yuanmingyuan West Road, Haidian District, Beijing, 100193, China.
| |
Collapse
|
13
|
Li B, Liu K, Weng Q, Li P, Wei W, Li Q, Chen J, Huang R, Wu W, Liu H. RNA-seq analysis reveals new candidate genes for drip loss in a Pietrain × Duroc × Landrace × Yorkshire population. Anim Genet 2016; 47:192-9. [DOI: 10.1111/age.12401] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/22/2015] [Indexed: 12/29/2022]
Affiliation(s)
- Bojiang Li
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Kaiqing Liu
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Qiannan Weng
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Pinghua Li
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Wei Wei
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Qifa Li
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Jie Chen
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Ruihua Huang
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Wangjun Wu
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| | - Honglin Liu
- Department of Animal Genetics, Breeding and Reproduction; College of Animal Science and Technology; Nanjing Agricultural University; Nanjing 210095 China
| |
Collapse
|
14
|
Bögeholz N, Pauls P, Bauer BK, Schulte JS, Dechering DG, Frommeyer G, Kirchhefer U, Goldhaber JI, Müller FU, Eckardt L, Pott C. Suppression of Early and Late Afterdepolarizations by Heterozygous Knockout of the Na+/Ca2+ Exchanger in a Murine Model. Circ Arrhythm Electrophysiol 2015; 8:1210-8. [PMID: 26338832 DOI: 10.1161/circep.115.002927] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Accepted: 08/13/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND The Na(+)/Ca(2+) exchanger (NCX) has been implied to cause arrhythmias. To date, information on the role of NCX in arrhythmogenesis derived from models with increased NCX expression, hypertrophy, and heart failure. Furthermore, the exact mechanism by which NCX exerts its potentially proarrhythmic effect, ie, by promoting early afterdepolarization (EAD) or delayed afterdepolarization (DAD) or both, is unknown. METHODS AND RESULTS We investigated isolated cardiomyocytes from a murine model with heterozygous knockout of NCX (hetKO) using the patch clamp and Ca(2+) imaging techniques. Action potential duration was shorter in hetKO with IKtot not being increased. The rate of spontaneous Ca(2+) release events and the rate of DADs were unaltered; however, DADs had lower amplitude in hetKO. A DAD triggered a spontaneous action potential significantly less often in hetKO when compared with wild-type. The occurrence of EADs was also drastically reduced in hetKO. ICa activity was reduced in hetKO, an effect that was abolished in the presence of the Ca(2+) buffer BAPTA. CONCLUSIONS Genetic suppression of NCX reduces both EADs and DADs. The following molecular mechanisms apply: (1) Although the absolute number of DADs is unaffected, an impaired translation of DADs into spontaneous action potentials results from a reduced DAD amplitude. (2) EADs are reduced in absolute number of occurrence, which is presumably a consequence of shortened action potential duration because of reduced NCX activity but also reduced ICa the latter possibly being caused by a direct modulation of Ca(2+)-dependent ICa inhibition by reduced NCX activity. This is the first study to demonstrate that genetic inhibition of NCX protects against afterdepolarizations and to investigate the underlying mechanisms.
Collapse
Affiliation(s)
- Nils Bögeholz
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.).
| | - Paul Pauls
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - B Klemens Bauer
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Jan S Schulte
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Dirk G Dechering
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Gerrit Frommeyer
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Uwe Kirchhefer
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Joshua I Goldhaber
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Frank U Müller
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Lars Eckardt
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| | - Christian Pott
- From the Division of Electrophysiology, Department of Cardiovascular Medicine (N.B., P.P., B.K.B., D.G.D., G.F., L.E., C.P.) and Institute of Pharmacology and Toxicology (P.P., B.K.B., J.S.S., U.K., F.U.M.), University Hospital Münster, Münster, Germany; and Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.I.G.)
| |
Collapse
|
15
|
Kirchhof P, Tal T, Fabritz L, Klimas J, Nesher N, Schulte JS, Ehling P, Kanyshkova T, Budde T, Nikol S, Fortmueller L, Stallmeyer B, Müller FU, Schulze-Bahr E, Schmitz W, Zlotkin E, Kirchhefer U. First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heart. Circ Heart Fail 2014; 8:79-88. [PMID: 25424392 DOI: 10.1161/circheartfailure.113.001066] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND New therapeutic approaches to improve cardiac contractility without severe risk would improve the management of acute heart failure. Increasing systolic sodium influx can increase cardiac contractility, but most sodium channel activators have proarrhythmic effects that limit their clinical use. Here, we report the cardiac effects of a novel positive inotropic peptide isolated from the toxin of the Black Judean scorpion that activates neuronal tetrodotoxin-sensitive sodium channels. METHODS AND RESULTS All venoms and peptides were isolated from Black Judean Scorpions (Buthotus Hottentotta) caught in the Judean Desert. The full scorpion venom increased left ventricular function in sedated mice in vivo, prolonged ventricular repolarization, and provoked ventricular arrhythmias. An inotropic peptide (BjIP) isolated from the full venom by chromatography increased cardiac contractility but did neither provoke ventricular arrhythmias nor prolong cardiac repolarization. BjIP increased intracellular calcium in ventricular cardiomyocytes and prolonged inactivation of the cardiac sodium current. Low concentrations of tetrodotoxin (200 nmol/L) abolished the effect of BjIP on calcium transients and sodium current. BjIP did not alter the function of Nav1.5, but selectively activated the brain-type sodium channels Nav1.6 or Nav1.3 in cellular electrophysiological recordings obtained from rodent thalamic slices. Nav1.3 (SCN3A) mRNA was detected in human and mouse heart tissue. CONCLUSIONS Our pilot experiments suggest that selective activation of tetrodotoxin-sensitive neuronal sodium channels can safely increase cardiac contractility. As such, the peptide described here may become a lead compound for a new class of positive inotropic agents.
Collapse
Affiliation(s)
- Paulus Kirchhof
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.).
| | - Tzachy Tal
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Larissa Fabritz
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Jan Klimas
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Nir Nesher
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Jan S Schulte
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Petra Ehling
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Tatayana Kanyshkova
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Thomas Budde
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Sigrid Nikol
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Lisa Fortmueller
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Birgit Stallmeyer
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Frank U Müller
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Eric Schulze-Bahr
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Wilhelm Schmitz
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Eliahu Zlotkin
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| | - Uwe Kirchhefer
- From the Department of Cardiovascular Medicine (P.K., L.F., S.N., L.F.), Department of Pharmacology and Toxicology (J.K., J.S.S., F.U.M., W.S., U.K.), and Department of Cardiovascular Medicine, Institute for Genetics of Heart Disease (IfGH) (B.S., E.S.-B.), Hospital of the University of Muenster, Muenster, Germany; Center for Cardiovascular Sciences, School of Clinical and Experimental Medicine, and SWBH NHS Trust, University of Birmingham, Birmingham, United Kingdom (P.K., L.F.); Technion Israel Institute of Technology, Haifa, Israel (T.T.); Department of Animal and Cell Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (T.T., N.N., E.Z.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovak Republic (J.K.); Department of Neurology, and Division of Neuropathophysiology, Institute of Physiology I (P.E.) and Institute of Physiology I (T.K., T.B.), University of Muenster, Muenster, Germany; and Department of Clinical and Interventional Angiology, Asklepios Clinic St. Georg, Hamburg, Germany (S.N.)
| |
Collapse
|
16
|
Kirchhefer U, Brekle C, Eskandar J, Isensee G, Kučerová D, Müller FU, Pinet F, Schulte JS, Seidl MD, Boknik P. Cardiac function is regulated by B56α-mediated targeting of protein phosphatase 2A (PP2A) to contractile relevant substrates. J Biol Chem 2014; 289:33862-73. [PMID: 25320082 DOI: 10.1074/jbc.m114.598938] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Dephosphorylation of important myocardial proteins is regulated by protein phosphatase 2A (PP2A), representing a heterotrimer that is comprised of catalytic, scaffolding, and regulatory (B) subunits. There is a multitude of B subunit family members directing the PP2A holoenzyme to different myocellular compartments. To gain a better understanding of how these B subunits contribute to the regulation of cardiac performance, we generated transgenic (TG) mice with cardiomyocyte-directed overexpression of B56α, a phosphoprotein of the PP2A-B56 family. The 2-fold overexpression of B56α was associated with an enhanced PP2A activity that was localized mainly in the cytoplasm and myofilament fraction. Contractility was enhanced both at the whole heart level and in isolated cardiomyocytes of TG compared with WT mice. However, peak amplitude of [Ca]i did not differ between TG and WT cardiomyocytes. The basal phosphorylation of cardiac troponin inhibitor (cTnI) and the myosin-binding protein C was reduced by 26 and 35%, respectively, in TG compared with WT hearts. The stimulation of β-adrenergic receptors by isoproterenol (ISO) resulted in an impaired contractile response of TG hearts. At a depolarizing potential of -5 mV, the ICa,L current density was decreased by 28% after administration of ISO in TG cardiomyocytes. In addition, the ISO-stimulated phosphorylation of phospholamban at Ser(16) was reduced by 27% in TG hearts. Thus, the increased PP2A-B56α activity in TG hearts is localized to specific subcellular sites leading to the dephosphorylation of important contractile proteins. This may result in higher myofilament Ca(2+) sensitivity and increased basal contractility in TG hearts. These effects were reversed by β-adrenergic stimulation.
Collapse
Affiliation(s)
- Uwe Kirchhefer
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Christiane Brekle
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - John Eskandar
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Gunnar Isensee
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Dana Kučerová
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Frank U Müller
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Florence Pinet
- INSERM, U744, Institut Pasteur de Lille, 59019 Lille, France
| | - Jan S Schulte
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Matthias D Seidl
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| | - Peter Boknik
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, D-48149 Münster, Germany and
| |
Collapse
|
17
|
Meoli L, Isensee J, Zazzu V, Nabzdyk CS, Soewarto D, Witt H, Foryst-Ludwig A, Kintscher U, Noppinger PR. Sex- and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice. Gene 2014; 540:210-6. [PMID: 24582972 DOI: 10.1016/j.gene.2014.02.036] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 12/09/2013] [Accepted: 02/19/2014] [Indexed: 12/26/2022]
Abstract
The G protein-coupled receptor 30 (GPR30) has been claimed as an estrogen receptor. However, the literature reports controversial findings and the physiological function of GPR30 is not fully understood yet. Consistent with studies assigning a role of GPR30 in the cardiovascular and metabolic systems, GPR30 expression has been reported in small arterial vessels, pancreas and chief gastric cells of the stomach. Therefore, we hypothesized a role of GPR30 in the onset and progression of cardiovascular and metabolic diseases. In order to test our hypothesis, we investigated the effects of a high-fat diet on the metabolic and cardiovascular profiles of Gpr30-deficient mice (GPR30-lacZ mice). We found that GPR30-lacZ female, rather than male, mice had significant lower levels of HDL along with an increase in fat liver accumulation as compared to control mice. However, two indicators of cardiac performance assessed by echocardiography, ejection fraction and fractional shortening were both decreased in an age-dependent manner only in Gpr30-lacZ male mice. Collectively our results point to a potential role of Gpr30 in preserving lipid metabolism and cardiac function in a sex- and age-dependent fashion.
Collapse
Affiliation(s)
- Luca Meoli
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany.
| | - Jörg Isensee
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Valeria Zazzu
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Christoph S Nabzdyk
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Dian Soewarto
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Henning Witt
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Anna Foryst-Ludwig
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | - Ulrich Kintscher
- Center for Cardiovascular Research-Charité, Hessische Str. 3-4, 10115 Berlin, Germany
| | | |
Collapse
|
18
|
Kirchhefer U, Heinick A, König S, Kristensen T, Müller FU, Seidl MD, Boknik P. Protein phosphatase 2A is regulated by protein kinase Cα (PKCα)-dependent phosphorylation of its targeting subunit B56α at Ser41. J Biol Chem 2013; 289:163-76. [PMID: 24225947 DOI: 10.1074/jbc.m113.507996] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Protein phosphatase 2A (PP2A) is a family of multifunctional serine/threonine phosphatases consisting of a catalytic C, a structural A, and a regulatory B subunit. The substrate and therefore the functional specificity of PP2A are determined by the assembly of the enzyme complex with the appropriate regulatory B subunit families, namely B55, B56, PR72, or PR93/PR110. It has been suggested that additional levels of regulating PP2A function may result from the phosphorylation of B56 isoforms. In this study, we identified a novel phosphorylation site at Ser(41) of B56α. This phosphoamino acid residue was efficiently phosphorylated in vitro by PKCα. We detected a 7-fold higher phosphorylation of B56α in failing human hearts compared with nonfailing hearts. Purified PP2A dimeric holoenzyme (subunits C and A) was able to dephosphorylate PKCα-phosphorylated B56α. The potency of B56α for PP2A inhibition was markedly increased by PKCα phosphorylation. PP2A activity was also reduced in HEK293 cells transfected with a B56α mutant, where serine 41 was replaced by aspartic acid, which mimics phosphorylation. More evidence for a functional role of PKCα-dependent phosphorylation of B56α was derived from Fluo-4 fluorescence measurements in phenylephrine-stimulated Flp293 cells. The endoplasmic reticulum Ca(2+) release was increased by 23% by expression of the pseudophosphorylated form compared with wild-type B56α. Taken together, our results suggest that PKCα can modify PP2A activity by phosphorylation of B56α at Ser(41). This interplay between PKCα and PP2A represents a new mechanism to regulate important cellular functions like cellular Ca(2+) homeostasis.
Collapse
Affiliation(s)
- Uwe Kirchhefer
- From the Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, 48149 Münster, Germany
| | | | | | | | | | | | | |
Collapse
|
19
|
Chopra N, Knollmann BC. Triadin regulates cardiac muscle couplon structure and microdomain Ca(2+) signalling: a path towards ventricular arrhythmias. Cardiovasc Res 2013; 98:187-91. [PMID: 23396608 DOI: 10.1093/cvr/cvt023] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Since the discovery of triadin >20 years ago as one of the major proteins located in the junctional sarcoplasmic reticulum, the field has come a long way in understanding the pivotal role of triadin in orchestrating sarcoplasmic reticulum Ca(2+)-release and hence excitation-contraction (EC) coupling. Building on the information gathered from earlier lipid bilayer and myocyte overexpression studies, the gene-targeted ablation of Trdn demonstrated triadin's indispensable role for maintaining the structural integrity of the couplon. More recently, the discovery of inherited and acquired diseases displaying altered expression and function of triadin has further emphasized the role of triadin in health and disease. Novel therapeutic approaches could be aimed at correcting the loss of triadin in diseased hearts, and thereby correcting the sub-cellular EC coupling defect. This review summarizes current concepts of the impact of triadin on cardiac EC coupling with a focus towards triadin's role for ventricular arrhythmia.
Collapse
Affiliation(s)
- Nagesh Chopra
- Division of Cardiovascular Medicine, Arrhythmia Unit, Brigham and Women's Hospital, Boston, MA, USA
| | | |
Collapse
|
20
|
FK506 binding proteins: Cellular regulators of intracellular Ca2+ signalling. Eur J Pharmacol 2013; 700:181-93. [DOI: 10.1016/j.ejphar.2012.12.029] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Revised: 12/04/2012] [Accepted: 12/18/2012] [Indexed: 02/04/2023]
|
21
|
Kučerová D, Baba HA, Bokník P, Fabritz L, Heinick A, Mát'uš M, Müller FU, Neumann J, Schmitz W, Kirchhefer U. Modulation of SR Ca2+ release by the triadin-to-calsequestrin ratio in ventricular myocytes. Am J Physiol Heart Circ Physiol 2012; 302:H2008-17. [PMID: 22427521 DOI: 10.1152/ajpheart.00457.2011] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Calsequestrin (CSQ) is a Ca(2+) storage protein that interacts with triadin (TRN), the ryanodine receptor (RyR), and junctin (JUN) to form a macromolecular tetrameric Ca(2+) signaling complex in the cardiac junctional sarcoplasmic reticulum (SR). Heart-specific overexpression of CSQ in transgenic mice (TG(CSQ)) was associated with heart failure, attenuation of SR Ca(2+) release, and downregulation of associated junctional SR proteins, e.g., TRN. Hence, we tested whether co-overexpression of CSQ and TRN in mouse hearts (TG(CxT)) could be beneficial for impaired intracellular Ca(2+) signaling and contractile function. Indeed, the depressed intracellular Ca(2+) concentration ([Ca](i)) peak amplitude in TG(CSQ) was normalized by co-overexpression in TG(CxT) myocytes. This effect was associated with changes in the expression of cardiac Ca(2+) regulatory proteins. For example, the protein level of the L-type Ca(2+) channel Ca(v)1.2 was higher in TG(CxT) compared with TG(CSQ). Sarco(endo)plasmic reticulum Ca(2+)-ATPase 2a (SERCA2a) expression was reduced in TG(CxT) compared with TG(CSQ), whereas JUN expression and [(3)H]ryanodine binding were lower in both TG(CxT) and TG(CSQ) compared with wild-type hearts. As a result of these expressional changes, the SR Ca(2+) load was higher in both TG(CxT) and TG(CSQ) myocytes. In contrast to the improved cellular Ca(2+), transient co-overexpression of CSQ and TRN resulted in a reduced survival rate, an increased cardiac fibrosis, and a decreased basal contractility in catheterized mice, working heart preparations, and isolated myocytes. Echocardiographic and hemodynamic measurements revealed a depressed cardiac performance after isoproterenol application in TG(CxT) compared with TG(CSQ). Our results suggest that co-overexpression of CSQ and TRN led to a normalization of the SR Ca(2+) release compared with TG(CSQ) mice but a depressed contractile function and survival rate probably due to cardiac fibrosis, a lower SERCA2a expression, and a blunted response to β-adrenergic stimulation. Thus the TRN-to-CSQ ratio is a critical modulator of the SR Ca(2+) signaling.
Collapse
Affiliation(s)
- Dana Kučerová
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Münster, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Schulte JS, Seidl MD, Nunes F, Freese C, Schneider M, Schmitz W, Müller FU. CREB critically regulates action potential shape and duration in the adult mouse ventricle. Am J Physiol Heart Circ Physiol 2012; 302:H1998-2007. [PMID: 22427515 DOI: 10.1152/ajpheart.00057.2011] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The cAMP response element binding protein (CREB) belongs to the CREB/cAMP response element binding modulator/activating transcription factor 1 family of cAMP-dependent transcription factors mediating a regulation of gene transcription in response to cAMP. Chronic stimulation of β-adrenergic receptors and the cAMP-dependent signal transduction pathway by elevated plasma catecholamines play a central role in the pathogenesis of heart failure. Ion channel remodeling, particularly a decreased transient outward current (I(to)), and subsequent action potential (AP) prolongation are hallmarks of the failing heart. Here, we studied the role of CREB for ion channel regulation in mice with a cardiomyocyte-specific knockout of CREB (CREB KO). APs of CREB KO cardiomyocytes were prolonged with increased AP duration at 50 and 70% repolarization and accompanied by a by 51% reduction of I(to) peak amplitude as detected in voltage-clamp measurements. We observed a 29% reduction of Kcnd2/Kv4.2 mRNA in CREB KO cardiomyocytes mice while the other I(to)-related channel subunits Kv4.3 and KChIP2 were not different between groups. Accordingly, Kv4.2 protein was reduced by 37% in CREB KO. However, we were not able to detect a direct regulation of Kv4.2 by CREB. The I(to)-dependent AP prolongation went along with an increase of I(Na) and a decrease of I(Ca,L) associated with an upregulation of Scn8a/Nav1.6 and downregulation of Cacna1c/Cav1.2 mRNA in CREB KO cardiomyocytes. Our results from mice with cardiomyocyte-specific inactivation of CREB definitively indicate that CREB critically regulates the AP shape and duration in the mouse ventricle, which might have an impact on ion channel remodeling in situations of altered cAMP-dependent signaling like heart failure.
Collapse
Affiliation(s)
- J S Schulte
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany.
| | | | | | | | | | | | | |
Collapse
|
23
|
Pönicke K, Gergs U, Buchwalow IB, Hauptmann S, Neumann J. On the presence of serotonin in mammalian cardiomyocytes. Mol Cell Biochem 2012; 365:301-12. [PMID: 22367115 DOI: 10.1007/s11010-012-1270-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Accepted: 02/16/2012] [Indexed: 10/28/2022]
Abstract
Pleiotropic effects of serotonin (5-HT) in the cardiovascular system are well documented. However, it remains to be elucidated, whether 5-HT is present in adult mammalian cardiomyocytes. To address this issue, we investigated the levels of 5-HT in blood, plasma, platelets, cardiac tissue, and cardiomyocytes from adult mice and for comparison in human right atrial tissue. Immunohistochemically, 5-HT was hardly found in mouse cardiac tissue, but small amounts could be detected in renal preparations, whereas adrenal preparations revealed a strong positive immunoreaction for 5-HT. Using a sensitive HPLC detection system, 5-HT was also detectable in the mouse heart and human atrium. Furthermore, we could identify 5-HT in isolated cardiomyocytes from adult mice. These findings were supported by detection of the activity of 5-HT-forming enzymes-tryptophan hydroxylase and aromatic L-amino acid decarboxylase-in isolated cardiomyocytes from adult mice and by inhibition of these enzymes with p-chlorophenylalanine and 3-hydroxybenzyl hydrazine. Addition of the first intermediate of 5-HT generation, that is 5-hydroxytryptophan, enhanced the 5-HT level and inhibition of monoamine oxidase by tranylcypromine further increased the level of 5-HT. Our findings reveal the presence and synthesis of 5-HT in cardiomyocytes of the mammalian heart implying that 5-HT may play an autocrine and/or paracrine role in the heart.
Collapse
Affiliation(s)
- Klaus Pönicke
- Medical Faculty, Institute of Pharmacology and Toxicology, Martin-Luther-University Halle-Wittenberg, Magdeburger Str. 4, 06112, Halle (Saale), Germany
| | | | | | | | | |
Collapse
|
24
|
Gergs U, Boknik P, Buchwalow IB, Fabritz L, Gründker N, Kucerova D, Matus M, Werner F, Schmitz W, Neumann J. Modulation of cardiac contractility by serine/threonine protein phosphatase type 5. Int J Cardiol 2012; 154:116-21. [DOI: 10.1016/j.ijcard.2010.09.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 07/28/2010] [Accepted: 09/05/2010] [Indexed: 10/19/2022]
|
25
|
Nader M, Westendorp B, Hawari O, Salih M, Stewart AFR, Leenen FHH, Tuana BS. Tail-anchored membrane protein SLMAP is a novel regulator of cardiac function at the sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2011; 302:H1138-45. [PMID: 22180652 DOI: 10.1152/ajpheart.00872.2011] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Sarcolemmal membrane-associated proteins (SLMAPs) are components of cardiac membranes involved in excitation-contraction (E-C) coupling. Here, we assessed the role of SLMAP in cardiac structure and function. We generated transgenic (Tg) mice with cardiac-restricted overexpression of SLMAP1 bearing the transmembrane domain 2 (TM2) to potentially interfere with endogenous SLMAP through homodimerization and subcellular targeting. Histological examination revealed vacuolated myocardium; the severity of which correlated with the expression level of SLMAP1-TM2. High resolution microscopy showed dilation of the sarcoplasmic reticulum/endoplasmic reticulum (SR/ER) and confocal imaging combined with biochemical analysis indicated targeting of SLMAP1-TM2 to the SR/ER membranes and inappropriate homodimerization. Older (28 wk of age) Tg mice exhibited reduced contractility with impaired relaxation as assessed by left ventricle pressure monitoring. The ventricular dysfunction was associated with electrophysiological abnormalities (elongated QT interval). Younger (5 wk of age) Tg mice also exhibited an elongated QT interval with minimal functional disturbances associated with the activation of the fetal gene program. They were less responsive to isoproterenol challenge (ΔdP/dt(max)) and developed electrical and left ventricular pressure alternans. The altered electrophysiological and functional disturbances in Tg mice were associated with diminished expression level of calcium cycling proteins of the sarcoplasmic reticulum such as the ryanodine receptor, Ca(2+)-ATPase, calsequestrin, and triadin (but not phospholamban), as well as significantly reduced calcium uptake in microsomal fractions. These data demonstrate that SLMAP is a regulator of E-C coupling at the level of the SR and its perturbation results in progressive deterioration of cardiac electrophysiology and function.
Collapse
Affiliation(s)
- Moni Nader
- Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
26
|
Protein phosphatase 2A affects myofilament contractility in non-failing but not in failing human myocardium. J Muscle Res Cell Motil 2011; 32:221-33. [PMID: 21959857 PMCID: PMC3205269 DOI: 10.1007/s10974-011-9261-x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Accepted: 09/09/2011] [Indexed: 02/04/2023]
Abstract
Protein phosphatase (PP) type 2A is a multifunctional serine/threonine phosphatase that is involved in cardiac excitation-contraction coupling. The PP2A core enzyme is a dimer, consisting of a catalytic C and a scaffolding A subunit, which is targeted to several cardiac proteins by a regulatory B subunit. At present, it is controversial whether PP2A and its subunits play a critical role in end-stage human heart failure. Here we report that the application of purified PP2AC significantly increased the Ca2+-sensitivity (ΔpCa50=0.05±0.01) of the contractile apparatus in isolated skinned myocytes of non-failing (NF) hearts. A higher phosphorylation of troponin I (cTnI) was found at protein kinase A sites (Ser23/24) in NF compared to failing myocardium. The basal Ca2+-responsiveness of myofilaments was enhanced in myocytes of ischemic (ICM, ΔpCa50=0.10±0.03) and dilated (DCM, ΔpCa50=0.06±0.04) cardiomyopathy compared to NF. However, in contrast to NF myocytes the treatment with PP2AC did not shift force-pCa relationships in failing myocytes. The higher basal Ca2+-sensitivity in failing myocytes coincided with a reduced protein expression of PP2AC in left ventricular tissue from patients suffering from ICM and DCM (by 50 and 56% compared to NF, respectively). However, PP2A activity was unchanged in failing hearts despite an increase of both total PP and PP1 activity. The expression of PP2AB56α was also decreased by 51 and 62% in ICM and DCM compared to NF, respectively. The phosphorylation of cTnI at Ser23/24 was reduced by 66 and 49% in ICM and DCM compared to NF hearts, respectively. Our results demonstrate that PP2A increases myofilament Ca2+-sensitivity in NF human hearts, most likely via cTnI dephosphorylation. This effect is not present in failing hearts, probably due to the lower baseline cTnI phosphorylation in failing compared to non-failing hearts.
Collapse
|
27
|
Punkt K, Kusche T, Günther S, Adams V, Jones LR, Neumann J. Changes in metabolic profile and population of skeletal muscle fibers of mice overexpressing calsequestrin: influence of losartan. Acta Histochem 2011; 113:547-55. [PMID: 20619444 DOI: 10.1016/j.acthis.2010.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Revised: 05/26/2010] [Accepted: 05/30/2010] [Indexed: 11/30/2022]
Abstract
In heart failure, exertional fatigue of skeletal muscles can occur. A transgenic mouse overexpressing calsequestrin can be regarded as an animal model of heart failure. The aims of the present study were to investigate, whether at the time of cardiac failure the composition of fiber types of skeletal muscles was altered, what kind of alterations in glycolytic and oxidative enzyme activities occurred in different muscle fiber types and whether these were affected by the administration of the angiotensin II receptor blocker, losartan. Hemodynamic parameters were determined using a working heart preparation. Four groups of mice were investigated: wild-type (WT) mice and transgenic (TG) mice overexpressing calsequestrin, with and without losartan treatment. Enzyme activities were measured in homogenates of Rectus femoris muscle and in muscle fibers, which were typed by their metabolic profile. Calcineurin expression was measured by Western blotting. Succinate dehydrogenase activity was increased by 275% in R. femoris muscle homogenates of TG compared to WT mice. This was due to a 57% increase in slow oxidative fibers, which was accompanied by an increased calcineurin expression in TG muscles. This increase was attenuated by losartan treatment. With respect to glycerol-3-phosphate-dehydrogenase (GPDH), no difference was evident comparing WT and TG. Treatment with losartan resulted in a down-regulation of GPDH in WT and TG. In conclusion, changes in skeletal muscles occur in this mouse model of heart failure and these changes were antagonized by losartan. In contrast to heart failure patients, in the mouse model a shift to the oxidative phenotype of skeletal muscle was noted, possibly due to enhanced calcineurin expression.
Collapse
Affiliation(s)
- Karla Punkt
- Institute of Anatomy, University of Leipzig, Germany.
| | | | | | | | | | | |
Collapse
|
28
|
Sarcoplasmic reticulum Ca2+ release in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2011; 51:682-8. [PMID: 21871897 DOI: 10.1016/j.yjmcc.2011.08.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2008] [Revised: 07/19/2011] [Accepted: 08/10/2011] [Indexed: 11/22/2022]
Abstract
In the neonatal mammalian heart, the role of ryanodine receptor (=Ca(2+) release channel)-mediated sarcoplasmic reticulum (SR) Ca(2+) release for excitation-contraction coupling is still a matter of debate. Using an adenoviral system, we overexpressed separately the junctional SR proteins triadin, junctin, and calsequestrin, which are probably involved in regulation of ryanodine receptor function. Infection of neonatal rat cardiac myocytes with triadin, junctin, or calsequestrin viruses, controlled by green fluorescent protein expression, resulted in an increased protein level of the corresponding transgenes. Measurement of Ca(2+) transients of infected cardiac myocytes revealed unchanged peak amplitudes under basal conditions but with overexpression of calsequestrin and triadin caffeine-releasable SR Ca(2+) content was increased. Our results demonstrate that an increased expression of triadin or calsequestrin is associated with an increased SR Ca(2+) storage but unchanged Ca(2+) signaling in neonatal rat cardiac myocytes. This is consistent with an ancillary role of the sarcoplasmic reticulum in excitation-contraction coupling in the developing mammalian heart.
Collapse
|
29
|
Günther S, Baba HA, Hauptmann S, Holzhausen HJ, Grossmann C, Punkt K, Kusche T, Jones LR, Gergs U, Neumann J. Losartan reduces mortality in a genetic model of heart failure. Naunyn Schmiedebergs Arch Pharmacol 2010; 382:265-78. [PMID: 20697885 DOI: 10.1007/s00210-010-0544-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2010] [Accepted: 07/21/2010] [Indexed: 01/10/2023]
Abstract
Altered Ca(2+) homoeostasis accompanies heart failure. As a model of heart failure, transgenic mice (TG) with selective overexpression of calsequestrin (CSQ) in the heart were used. CSQ is the main Ca(2+) binding protein in the lumen of the junctional sarcoplasmic reticulum. Overexpression of CSQ leads to hypertrophy, fibrosis, heart failure, cardiac arrhythmias, and ultimately premature death compared to littermate controls (WT). In the present study, cardiac hypertrophy was noted at 2 months of age (relative heart weight 6.4 +/- 0.2 mg/g in WT and 11.2 +/- 0.3 mg/g in TG, n = 7, p < 0.05) which progressed at 5 months of age (relative heart weight 15.5 +/- 1.1 mg/g in TG, n = 11). Furthermore, an increased degree of fibrosis (from 0.29 +/- 0.04 in WT to 0.77 +/- 0.06 in TG, n = 8, p < 0.05) was quantified by sirius red staining. Cardiac function was greatly impaired in TG as exemplified by reduced pressure development and cardiac arrhythmias. It is hypothesized that losartan, an inhibitor of angiotensin II receptors, might be able to attenuate these detrimental effects. Hence, TG and WT were treated for 1 or 4 months perorally with losartan (5 mg/kg/day) or solvent alone (control conditions) starting at 4 weeks of age. Under control conditions, none of the WT died within the observation period whereas all TG died within 9 months. Losartan treatment reduced the mortality of TG: Mean life span was raised from 116 to 193 days (n = 18 end, p < 0.05). Likewise, losartan reduced relative heart weight and the degree of fibrosis. In addition, losartan improved hemodynamic parameters, like left ventricular pressure and its first derivative. However, losartan treatment did not modify overexpression of CSQ in the heart of TG. These results imply that the angiotensin II receptor (type 1) contributes to heart failure due to CSQ overexpression, as its blockade improved survival.
Collapse
Affiliation(s)
- Sophie Günther
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Gergs U, Baumann M, Böckler A, Buchwalow IB, Ebelt H, Fabritz L, Hauptmann S, Keller N, Kirchhof P, Klöckner U, Pönicke K, Rueckschloss U, Schmitz W, Werner F, Neumann J. Cardiac overexpression of the human 5-HT4 receptor in mice. Am J Physiol Heart Circ Physiol 2010; 299:H788-98. [PMID: 20639221 DOI: 10.1152/ajpheart.00691.2009] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Serotonin (5-HT) exerts pleiotropic effects in the human cardiovascular system. Some of the effects are thought to be mediated via 5-HT(4) receptors, which are expressed in the human atrium and in ventricular tissue. However, a true animal model to study these receptors in more detail has been hitherto lacking. Therefore, we generated, for the first time, a transgenic (TG) mouse with cardiac myocyte-specific expression of the human 5-HT(4) receptor. RT-PCR and immunohistochemistry revealed expression of the receptor at the mRNA and protein levels. Stimulation of isolated cardiac preparations by isoproterenol increased phospholamban phosphorylation at Ser(16) and Thr(17) sites. 5-HT increased phosphorylation only in TG mice but not in wild-type (WT) mice. Furthermore, 5-HT increased contractility in isolated perfused hearts from TG mice but not WT mice. These effects of 5-HT could be blocked by the 5-HT(4) receptor-selective antagonist GR-125487. An intravenous infusion of 5-HT increased left ventricular contractility in TG mice but not in WT mice. Similarly, the increase in contractility by 5-HT in isolated cardiomyocytes from TG mice was accompanied by and probably mediated through an increase in L-type Ca(2+) channel current and in Ca(2+) transients. In intact animals, echocardiography revealed an inotropic and chronotropic effect of subcutaneously injected 5-HT in TG mice but not in WT mice. In isolated hearts from TG mice, spontaneous polymorphic atrial arrhythmias were noted. These findings demonstrate the functional expression of 5-HT(4) receptors in the heart of TG mice, and a potential proarrhythmic effect in the atrium. Therefore, 5-HT(4) receptor-expressing mice might be a useful model to mimic the human heart, where 5-HT(4) receptors are present and functional in the atrium and ventricle of the healthy and failing heart, and to investigate the influence of 5-HT in the development of cardiac arrhythmias and heart failure.
Collapse
Affiliation(s)
- Ulrich Gergs
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Magdeburger Strasse 4, Halle D-06112, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kirchhefer U, Wehrmeister D, Postma AV, Pohlentz G, Mormann M, Kucerova D, Müller FU, Schmitz W, Schulze-Bahr E, Wilde AA, Neumann J. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. J Mol Cell Cardiol 2010; 49:95-105. [DOI: 10.1016/j.yjmcc.2010.03.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2009] [Revised: 03/04/2010] [Accepted: 03/08/2010] [Indexed: 10/19/2022]
|
32
|
Boldt A, Gergs U, Frenker J, Simm A, Silber RE, Klöckner U, Neumann J. Inotropic effects of L-lysine in the mammalian heart. Naunyn Schmiedebergs Arch Pharmacol 2009; 380:293-301. [PMID: 19662383 DOI: 10.1007/s00210-009-0439-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2009] [Accepted: 07/16/2009] [Indexed: 10/20/2022]
Abstract
We studied the effects of L-lysine in cardiac preparations of mice and men. Of note, L-lysine increased force of contraction in a concentration- and time-dependent manner in isolated electrically paced left atrium of mouse and in human right atrium. It further increased heart rate and left ventricular pressure in the isolated perfused mouse heart. In isolated adult mouse cardiomyocytes, the contractility as assessed by edge detection was increased as well as the Ca(2+) transients after electrically pacing by field stimulation. However, using the patch clamp technique, no effect of L-lysine on action potential duration from a constant holding potential or on current through L-type calcium channels could be observed. However, L-lysine led to a depolarization of unclamped cells. Furthermore, effects of L-lysine were stereospecific, as they were not elicited by D-lysine. The inotropic effects of L-lysine were not abrogated by additionally applied L-ornithine or L-arginine (known inhibitors of lysine transport). However, L-lysine (5 mM) shifted the concentration-response curve for a positive inotropic effect of 5-hydroxytryptamine (5-HT; serotonin) in atrium of transgenic mice (with cardiac specific overexpression of 5-HT(4) receptors) to higher concentrations. In summary, we describe a novel positive inotropic effect of an essential amino acid, L-lysine, in the mammalian heart. One might speculate that L-lysine treatment under certain conditions could sustain cardiac performance. Moreover, L-lysine is able to block, at least in part, cardiac 5-HT(4) receptors.
Collapse
Affiliation(s)
- Andreas Boldt
- Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, 06112 Halle, Germany
| | | | | | | | | | | | | |
Collapse
|
33
|
Feng Y, Valley MT, Lazar J, Yang AL, Bronson RT, Firestein S, Coetzee WA, Manley JL. SRp38 regulates alternative splicing and is required for Ca(2+) handling in the embryonic heart. Dev Cell 2009; 16:528-38. [PMID: 19386262 DOI: 10.1016/j.devcel.2009.02.009] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Revised: 01/09/2009] [Accepted: 02/12/2009] [Indexed: 11/18/2022]
Abstract
SRp38 is an atypical SR protein splicing regulator. To define the functions of SRp38 in vivo, we generated SRp38 null mice. The majority of homozygous mutants survived only until E15.5 and displayed multiple cardiac defects. Evaluation of gene expression profiles in the SRp38(-/-) embryonic heart revealed a defect in processing of the pre-mRNA encoding cardiac triadin, a protein that functions in regulation of Ca(2+) release from the sarcoplasmic reticulum during excitation-contraction coupling. This defect resulted in significantly reduced levels of triadin, as well as those of the interacting protein calsequestrin 2. Purified SRp38 was shown to bind specifically to the regulated exon and to modulate triadin splicing in vitro. Extending these results, isolated SRp38(-/-) embryonic cardiomyocytes displayed defects in Ca(2+) handling compared with wild-type controls. Taken together, our results demonstrate that SRp38 regulates cardiac-specific alternative splicing of triadin pre-mRNA and, reflecting this, is essential for proper Ca(2+) handling during embryonic heart development.
Collapse
Affiliation(s)
- Ying Feng
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Beard NA, Wei L, Dulhunty AF. Ca(2+) signaling in striated muscle: the elusive roles of triadin, junctin, and calsequestrin. EUROPEAN BIOPHYSICS JOURNAL: EBJ 2009; 39:27-36. [PMID: 19434403 DOI: 10.1007/s00249-009-0449-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2009] [Revised: 03/22/2009] [Accepted: 03/27/2009] [Indexed: 10/20/2022]
Abstract
This review focuses on molecular interactions between calsequestrin, triadin, junctin and the ryanodine receptor in the lumen of the sarcoplasmic reticulum. These interactions modulate changes in Ca(2+) release in response to changes in the Ca(2+) load within the sarcoplasmic reticulum store in striated muscle and are of fundamental importance to Ca(2+) homeostasis, since massive adaptive changes occur when expression of the proteins is manipulated, while mutations in calsequestrin lead to functional changes which can be fatal. We find that calsequestrin plays a different role in the heart and skeletal muscle, enhancing Ca(2+) release in the heart, but depressing Ca(2+) release in skeletal muscle. We also find that triadin and junctin exert independent influences on the ryanodine receptor in skeletal muscle where triadin alone modifies excitation-contraction coupling, while junctin alone supports functional interactions between calsequestrin and the ryanodine receptor.
Collapse
Affiliation(s)
- Nicole A Beard
- Muscle Research Group, John Curtin School of Medical Research, Australian National University, PO Box 334, Canberra, ACT, 2601, Australia
| | | | | |
Collapse
|
35
|
Junctin and triadin each activate skeletal ryanodine receptors but junctin alone mediates functional interactions with calsequestrin. Int J Biochem Cell Biol 2009; 41:2214-24. [PMID: 19398037 DOI: 10.1016/j.biocel.2009.04.017] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2008] [Revised: 04/12/2009] [Accepted: 04/20/2009] [Indexed: 11/23/2022]
Abstract
Normal Ca(2+) signalling in skeletal muscle depends on the membrane associated proteins triadin and junctin and their ability to mediate functional interactions between the Ca(2+) binding protein calsequestrin and the type 1 ryanodine receptor in the lumen of the sarcoplasmic reticulum. This important mechanism conserves intracellular Ca(2+) stores, but is poorly understood. Triadin and junctin share similar structures and are lumped together in models of interactions between skeletal muscle calsequestrin and ryanodine receptors, however their individual roles have not been examined at a molecular level. We show here that purified skeletal ryanodine receptors are similarly activated by purified triadin or purified junctin added to their luminal side, although a lack of competition indicated that the proteins act at independent sites. Surprisingly, triadin and junctin differed markedly in their ability to transmit information between skeletal calsequestrin and ryanodine receptors. Purified calsequestrin inhibited junctin/triadin-associated, or junctin-associated, ryanodine receptors and the calsequestrin re-associated channel complexes were further inhibited when luminal Ca(2+) fell from 1mM to <or=100 microM, as seen with native channels (containing endogenous calsequestrin/triadin/junctin). In contrast, skeletal calsequestrin had no effect on the triadin/ryanodine receptor complex and the channel activity of this complex increased when luminal Ca(2+) fell, as seen with purified channels prior to triadin/calsequestrin re-association. Therefore in this cell free system, junctin alone mediates signals between luminal Ca(2+), skeletal calsequestrin and skeletal ryanodine receptors and may curtail resting Ca(2+) leak from the sarcoplasmic reticulum. We suggest that triadin serves a different function which may dominate during excitation-contraction coupling.
Collapse
|
36
|
Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci U S A 2009; 106:7636-41. [PMID: 19383796 DOI: 10.1073/pnas.0902919106] [Citation(s) in RCA: 121] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Heart muscle excitation-contraction (E-C) coupling is governed by Ca(2+) release units (CRUs) whereby Ca(2+) influx via L-type Ca(2+) channels (Cav1.2) triggers Ca(2+) release from juxtaposed Ca(2+) release channels (RyR2) located in junctional sarcoplasmic reticulum (jSR). Although studies suggest that the jSR protein triadin anchors cardiac calsequestrin (Casq2) to RyR2, its contribution to E-C coupling remains unclear. Here, we identify the role of triadin using mice with ablation of the Trdn gene (Trdn(-/-)). The structure and protein composition of the cardiac CRU is significantly altered in Trdn(-/-) hearts. jSR proteins (RyR2, Casq2, junctin, and junctophilin 1 and 2) are significantly reduced in Trdn(-/-) hearts, whereas Cav1.2 and SERCA2a remain unchanged. Electron microscopy shows fragmentation and an overall 50% reduction in the contacts between jSR and T-tubules. Immunolabeling experiments show reduced colocalization of Cav1.2 with RyR2 and substantial Casq2 labeling outside of the jSR in Trdn(-/-) myocytes. CRU function is impaired in Trdn(-/-) myocytes, with reduced SR Ca(2+) release and impaired negative feedback of SR Ca(2+) release on Cav1.2 Ca(2+) currents (I(Ca)). Uninhibited Ca(2+) influx via I(Ca) likely contributes to Ca(2+) overload and results in spontaneous SR Ca(2+) releases upon beta-adrenergic receptor stimulation with isoproterenol in Trdn(-/-) myocytes, and ventricular arrhythmias in Trdn(-/-) mice. We conclude that triadin is critically important for maintaining the structural and functional integrity of the cardiac CRU; triadin loss and the resulting alterations in CRU structure and protein composition impairs E-C coupling and renders hearts susceptible to ventricular arrhythmias.
Collapse
|
37
|
Yuan Q, Han P, Dong M, Ren X, Zhou X, Chen S, Jones WK, Chu G, Wang HS, Kranias EG. Partial downregulation of junctin enhances cardiac calcium cycling without eliciting ventricular arrhythmias in mice. Am J Physiol Heart Circ Physiol 2009; 296:H1484-90. [PMID: 19286959 DOI: 10.1152/ajpheart.00229.2008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Human failing hearts exhibit significant decreases in junctin expression levels with almost nondetectable levels, which may be associated with premature death, induced by lethal cardiac arrhythmias, based on mouse models. However, the specific contribution of junctin to the delayed afterdepolarizations has been difficult to delineate in the phase of increased Na(+)-Ca(2+) exchanger activity accompanying junctin ablation. Thus we characterized the heterozygous junctin-deficient hearts, which expressed 54% of junctin levels and similar increases in Na(+)-Ca(2+) exchanger activity, as the null model. Cardiac contractile parameters, Ca(2+) transients, and sarcoplasmic reticulum Ca(2+) content were significantly increased in junctin heterozygous hearts, although they did not reach the levels of null hearts. However, Ca(2+) spark properties were not altered in heterozygous cardiomyocytes, compared with wild-types, and there were no aftercontractions elicited by the increased frequency of stimulation in the presence of isoproterenol, unlike the junctin-deficient cells. Furthermore, heterozygous mice did not exhibit an increased susceptibility to arrhythmia upon catecholamine challenge in vivo, and there were no premature deaths up to 1 yr of age. These findings suggest that a partial downregulation of junctin enhances sarcoplasmic reticulum Ca(2+) cycling but does not elicit cardiac arrhythmias even in the context of increased Na(+)-Ca(2+) exchanger activity.
Collapse
Affiliation(s)
- Qunying Yuan
- Dept. of Pharmacology and Cell Biophysics, Univ. of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0575, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lewin G, Matus M, Basu A, Frebel K, Rohsbach SP, Safronenko A, Seidl MD, Stümpel F, Buchwalow I, König S, Engelhardt S, Lohse MJ, Schmitz W, Müller FU. Critical role of transcription factor cyclic AMP response element modulator in beta1-adrenoceptor-mediated cardiac dysfunction. Circulation 2008; 119:79-88. [PMID: 19103994 DOI: 10.1161/circulationaha.108.786533] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND Chronic stimulation of the beta(1)-adrenoceptor (beta(1)AR) plays a crucial role in the pathogenesis of heart failure; however, underlying mechanisms remain to be elucidated. The regulation by transcription factors cAMP response element-binding protein (CREB) and cyclic AMP response element modulator (CREM) represents a fundamental mechanism of cyclic AMP-dependent gene control possibly implicated in beta(1)AR-mediated cardiac deterioration. METHODS AND RESULTS We studied the role of CREM in beta(1)AR-mediated cardiac effects, comparing transgenic mice with heart-directed expression of beta(1)AR in the absence and presence of functional CREM. CREM inactivation protected from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in beta(1)AR-overexpressing mice. Transcriptome and proteome analysis revealed a set of predicted CREB/CREM target genes including the cardiac ryanodine receptor, tropomyosin 1alpha, and cardiac alpha-actin as altered on the mRNA or protein level along with the improved phenotype in CREM-deficient beta(1)AR-transgenic hearts. CONCLUSIONS The results imply the regulation of genes by CREM as an important mechanism of beta(1)AR-induced cardiac damage in mice.
Collapse
Affiliation(s)
- Geertje Lewin
- Institute of Pharmacology and Toxicology, University of Münster, Münster, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Davis J, Westfall MV, Townsend D, Blankinship M, Herron TJ, Guerrero-Serna G, Wang W, Devaney E, Metzger JM. Designing heart performance by gene transfer. Physiol Rev 2008; 88:1567-651. [PMID: 18923190 DOI: 10.1152/physrev.00039.2007] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
The birth of molecular cardiology can be traced to the development and implementation of high-fidelity genetic approaches for manipulating the heart. Recombinant viral vector-based technology offers a highly effective approach to genetically engineer cardiac muscle in vitro and in vivo. This review highlights discoveries made in cardiac muscle physiology through the use of targeted viral-mediated genetic modification. Here the history of cardiac gene transfer technology and the strengths and limitations of viral and nonviral vectors for gene delivery are reviewed. A comprehensive account is given of the application of gene transfer technology for studying key cardiac muscle targets including Ca(2+) handling, the sarcomere, the cytoskeleton, and signaling molecules and their posttranslational modifications. The primary objective of this review is to provide a thorough analysis of gene transfer studies for understanding cardiac physiology in health and disease. By comparing results obtained from gene transfer with those obtained from transgenesis and biophysical and biochemical methodologies, this review provides a global view of cardiac structure-function with an eye towards future areas of research. The data presented here serve as a basis for discovery of new therapeutic targets for remediation of acquired and inherited cardiac diseases.
Collapse
Affiliation(s)
- Jennifer Davis
- Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Györke S, Carnes C. Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease. Pharmacol Ther 2008; 119:340-54. [PMID: 18675300 DOI: 10.1016/j.pharmthera.2008.06.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2008] [Accepted: 06/17/2008] [Indexed: 12/15/2022]
Abstract
In the heart, Ca(2+) released from the intracellular Ca(2+) storage site, the sarcoplasmic reticulum (SR), is the principal determinant of cardiac contractility. SR Ca(2+) release is controlled by dedicated molecular machinery, composed of the cardiac ryanodine receptor (RyR2) and a number of accessory proteins, including FKBP12.6, calsequestrin (CASQ2), triadin (TRD) and junctin (JN). Acquired and genetic defects in the components of the release channel complex result in a spectrum of abnormal Ca(2+) release phenotypes ranging from arrhythmogenic spontaneous Ca(2+) releases and Ca(2+) alternans to the uniformly diminished systolic Ca(2+) release characteristic of heart failure. In this article, we will present an overview of the structure and molecular components of the SR and Ca(2+) release machinery and its modulation by different intracellular factors, such as Ca(2+) levels inside the SR as well as phosphorylation and redox modification of RyR2s. We will also discuss the relationships between abnormal SR Ca(2+) release and various cardiac disease phenotypes, including, arrhythmias and heart failure, and consider SR Ca(2+) release as a potential therapeutic target.
Collapse
Affiliation(s)
- Sandor Györke
- Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, United States.
| | | |
Collapse
|
41
|
Grote-Wessels S, Baba HA, Boknik P, El-Armouche A, Fabritz L, Gillmann HJ, Kucerova D, Matus M, Muller FU, Neumann J, Schmitz M, Stumpel F, Theilmeier G, Wohlschlaeger J, Schmitz W, Kirchhefer U. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 2008; 79:464-71. [DOI: 10.1093/cvr/cvn113] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
42
|
Hong CS, Kwon SJ, Cho MC, Kwak YG, Ha KC, Hong B, Li H, Chae SW, Chai OH, Song CH, Li Y, Kim JC, Woo SH, Lee SY, Lee CO, Kim DH. Overexpression of junctate induces cardiac hypertrophy and arrhythmia via altered calcium handling. J Mol Cell Cardiol 2008; 44:672-82. [PMID: 18353357 DOI: 10.1016/j.yjmcc.2008.01.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2007] [Revised: 01/15/2008] [Accepted: 01/29/2008] [Indexed: 12/14/2022]
Abstract
Junctate-1 is a newly identified integral endoplasmic/sarcoplasmic reticulum Ca2+ binding protein. However, its functional role in the heart is unknown. In the present study, the consequences of constitutively overexpressed junctate in cardiomyocytes were investigated using transgenic (TG) mice overexpressing junctate-1. TG mice (8 weeks old) showed cardiac remodeling such as marked bi-atrial enlargement with intra-atrial thrombus and biventricular hypertrophy. The TG mice also showed bradycardia with atrial fibrillation, reduced amplitude and elongated decay time of Ca2+ transients, increased L-type Ca2+ current and prolonged action potential durations. Time-course study (2-8 weeks) showed an initially reduced SR function due to down-regulation of SERCA2 and calsequestrin followed by sarcolemmal protein expression and cardiac hypertrophy at later age. These sequential changes could well be correlated with the physiological changes. Adrenergic agonist treatment and subsequent biochemical study showed that junctate-1 TG mice (8 weeks old) were under local PKA signaling that could cause increased L-type Ca2+ current and reduced SR function. Junctate-1 in the heart is closely linked to the homeostasis of E-C coupling proteins and a sustained increase of junctate-1 expression leads to a severe cardiac remodeling and arrhythmias.
Collapse
Affiliation(s)
- Chang-Soo Hong
- Department of Biological Science, College of Natural Sciences, Daegu University, Gyeongsan, South Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Hong CS, Kwon SJ, Kim DH. Multiple functions of junctin and junctate, two distinct isoforms of aspartyl beta-hydroxylase. Biochem Biophys Res Commun 2007; 362:1-4. [PMID: 17706594 DOI: 10.1016/j.bbrc.2007.07.166] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2007] [Accepted: 07/24/2007] [Indexed: 11/19/2022]
Abstract
The single genomic locus, AbetaH-J-J, encodes three functionally distinct proteins aspartyl beta-hydroxylase, junctin and junctate by alternative splicing. Among these three proteins, junctin and junctate could play important roles in the regulation of intracellular Ca(2+) by regulating either Ca(2+) release from intracellular Ca(2+) stores or Ca(2+) influx in various biological processes. Here we review recent findings concerning the expressional regulations and the proposed functions of junctin and junctate.
Collapse
Affiliation(s)
- Chang-Soo Hong
- Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Soon-Jae Kwon
- Department of Life Science, Gwangju Institute of Science and Technology (GIST), 1 Oryong-dong, Buk-gu, Gwangju 500-712, Republic of Korea
| | - Do Han Kim
- Department of Life Science, Gwangju Institute of Science and Technology (GIST), 1 Oryong-dong, Buk-gu, Gwangju 500-712, Republic of Korea.
| |
Collapse
|
44
|
Kirchhefer U, Klimas J, Baba HA, Buchwalow IB, Fabritz L, Hüls M, Matus M, Müller FU, Schmitz W, Neumann J. Triadin is a critical determinant of cellular Ca cycling and contractility in the heart. Am J Physiol Heart Circ Physiol 2007; 293:H3165-74. [PMID: 17890426 DOI: 10.1152/ajpheart.00799.2007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Triadin is involved in the regulation of cardiac excitation-contraction coupling. However, the extent of its contribution to the regulation of sarcoplasmic reticulum (SR) Ca release remains unclear, because overexpression of triadin in single-transgenic mice was associated with the downregulation of its homologous protein, junctin. In the present study, this problem was circumvented by cross-breeding of mice with heart-directed overexpression of triadin and junctin (JxT). This resulted in a stable approximately threefold expression of total triadin but unchanged junctin protein. Transgenic mice exhibited cardiac hypertrophy and structural abnormalities of myofibrils. Measurement of cardiac function by echocardiography and edge detection in myocytes revealed an impaired relaxation in JxT mice. The stimulation of beta-adrenergic receptors resulted in a depressed contractility and an impaired relaxation in catheterized hearts and myocytes of JxT mice. The use of a maximum stimulation frequency (5 Hz) was associated with both a lower shortening and relengthening in isolated myocytes of JxT mice. The contractile effects in JxT myocytes were paralleled by similar changes of the intracellular Ca concentration ([Ca](i)) peak amplitude and Ca transient decay kinetics at basal conditions, under administration of isoproterenol, and with high-frequency stimulation. Finally, we found a higher caffeine-induced [Ca](i) peak amplitude in JxT myocytes. Our data show that the stable expression of triadin, independent of junctin expression, resulted in cardiac hypertrophy, prolonged basal relaxation, a depressed response to beta-adrenergic agonists, and altered Ca transients. Thus the maintenance of triadin expression is essential for normal SR Ca cycling and contractile function.
Collapse
Affiliation(s)
- Uwe Kirchhefer
- Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Münster, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Brenner JS, Dolmetsch RE. TrpC3 regulates hypertrophy-associated gene expression without affecting myocyte beating or cell size. PLoS One 2007; 2:e802. [PMID: 17726532 PMCID: PMC1950081 DOI: 10.1371/journal.pone.0000802] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2007] [Accepted: 07/21/2007] [Indexed: 11/19/2022] Open
Abstract
Pathological cardiac hypertrophy is associated with an increased risk of heart failure and cardiovascular mortality. Calcium (Ca2+) -regulated gene expression is essential for the induction of hypertrophy, but it is not known how myocytes distinguish between the Ca2+ signals that regulate contraction and those that lead to cardiac hypertrophy. We used in vitro neonatal rat ventricular myocytes to perform an RNA interference (RNAi) screen for ion channels that mediate Ca2+-dependent gene expression in response to hypertrophic stimuli. We identified several ion channels that are linked to hypertrophic gene expression, including transient receptor potential C3 (TrpC3). RNAi-mediated knockdown of TrpC3 decreases expression of hypertrophy-associated genes such as the A- and B-type natriuretic peptides (ANP and BNP) in response to numerous hypertrophic stimuli, while TrpC3 overexpression increases BNP expression. Furthermore, stimuli that induce hypertrophy dramatically increase TrpC3 mRNA levels. Importantly, whereas TrpC3-knockdown strongly reduces gene expression associated with hypertrophy, it has a negligible effect on cell size and on myocyte beating. These results suggest that Ca2+ influx through TrpC3 channels increases transcription of genes associated with hypertrophy but does not regulate the signaling pathways that control cell size or contraction. Thus TrpC3 may represent an important therapeutic target for the treatment of cardiac hypertrophy and heart failure.
Collapse
Affiliation(s)
- Jacob S. Brenner
- Program in Chemical and Systems Biology, Stanford University, Stanford, California, United States of America
- Department of Neurobiology, Stanford University, Stanford, California, United States of America
| | - Ricardo E. Dolmetsch
- Department of Neurobiology, Stanford University, Stanford, California, United States of America
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
46
|
Gergs U, Berndt T, Buskase J, Jones LR, Kirchhefer U, Müller FU, Schlüter KD, Schmitz W, Neumann J. On the role of junctin in cardiac Ca2+ handling, contractility, and heart failure. Am J Physiol Heart Circ Physiol 2007; 293:H728-34. [PMID: 17400717 DOI: 10.1152/ajpheart.01187.2006] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Junctin is a transmembrane protein located at the cardiac junctional sarcoplasmic reticulum (SR) and forms a quaternary complex with the Ca2+ release channel, triadin and calsequestrin. Impaired protein interactions within this complex may alter the Ca2+ sensitivity of the Ca2+ release channel and may lead to cardiac dysfunction, including hypertrophy, depressed contractility, and abnormal Ca2+ transients. To study the expression of junctin and, for comparison, triadin, in heart failure, we measured the levels of these proteins in SR from normal and failing human hearts. Junctin was below our level of detection in SR membranes from failing human hearts, and triadin was downregulated by 22%. To better understand the role of junctin in the regulation of Ca2+ homeostasis and contraction of cardiac myocytes, we used an adenoviral approach to overexpress junctin in isolated rat cardiac myocytes. A recombinant adenovirus encoding the green fluorescent protein served as a control. Infection of myocytes with the junctin-expressing virus resulted in an increased RNA and protein expression of junctin. Ca2+ transients showed a decreased maximum Ca2+ amplitude, and contractility of myocytes was depressed. Our results demonstrate that an increased expression of junctin is associated with an impaired Ca2+ homeostasis. Downregulation of junctin in human heart failure may thus be a compensatory mechanism.
Collapse
Affiliation(s)
- Ulrich Gergs
- Institut für Pharmakologie und Toxikologie, Martin-Luther-Universität Halle-Wittenberg, Magdeburger Strasse 4, 06112 Halle/Saale, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Terentyev D, Viatchenko-Karpinski S, Vedamoorthyrao S, Oduru S, Györke I, Williams SC, Györke S. Protein protein interactions between triadin and calsequestrin are involved in modulation of sarcoplasmic reticulum calcium release in cardiac myocytes. J Physiol 2007; 583:71-80. [PMID: 17569730 PMCID: PMC2277233 DOI: 10.1113/jphysiol.2007.136879] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
In cardiac muscle, intracellular Ca2+ release is controlled by a number of proteins including the ryanodine receptor (RyR2), calsequestrin (CASQ2), triadin-1 (Trd) and junctin (Jn) which form a complex in the junctional sarcoplasmic reticulum (SR) membrane. Within this complex, Trd appears to link CASQ2 to RyR2 although the functional significance of this interaction is unclear. In this study, we explored the functional importance of Trd-CASQ2 interactions for intracellular Ca2+ handling in rat ventricular myocytes. A peptide encompassing the homologous CASQ2 binding domain of Trd (residues 206-230 in the rat; TrdPt) was expressed in the lumen of the SR to disrupt Trd-CASQ2 interactions. Myocytes expressing TrdPt exhibited increased responsiveness of SR Ca2+ release to activation by ICa as manifested by flattened and broadened voltage dependency of the amplitude of cytosolic Ca2+ transients. Rhythmically paced, TrdPt-expressing myocytes exhibited spontaneous arrhythmogenic oscillations of intracellular Ca2+ and membrane potential that was not seen in control cells. In addition, the frequency of spontaneous Ca2+ sparks and Ca2+ waves was significantly increased in TrdPt-expressing, permeabilized myocytes. These alterations in SR Ca2+ release were accompanied by a significant decrease in basal free intra-SR[Ca2+] and total SR Ca2+ content in TrdPt-expressing cells. At the same time a synthetic peptide corresponding to the CASQ2 binding domain of Trd produced no direct effects on the activity of single RyR2 channels incorporated into lipid bilayers while interfering with the ability of CASQ2 to inhibit the RyR2 channel. These results suggest that CASQ2 stabilizes SR Ca2+ release by inhibiting the RyR2 channel through interaction with Trd. They also show that intracellular Ca2+ cycling in the heart relies on coordinated interactions between proteins of the RyR2 channel complex and that disruption of these interactions may represent a molecular mechanism for cardiac disease.
Collapse
Affiliation(s)
- Dmitry Terentyev
- Department of Physiology and Cell Biology, 505 Davis Heart and Lung Research Institute, The Ohio State University, 473 W 12th Ave, Columbus, OH 43210, USA
| | | | | | | | | | | | | |
Collapse
|
48
|
Kirchhof P, Klimas J, Fabritz L, Zwiener M, Jones LR, Schäfers M, Hermann S, Boknik P, Schmitz W, Breithardt G, Kirchhefer U, Neumann J. Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. J Mol Cell Cardiol 2007; 42:962-71. [PMID: 17408688 DOI: 10.1016/j.yjmcc.2007.02.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Revised: 02/03/2007] [Accepted: 02/27/2007] [Indexed: 10/23/2022]
Abstract
Reduced function of the cardiac ryanodine receptor or calsequestrin causes catecholaminergic ventricular tachycardia (VT). These proteins regulate sarcoplasmic Ca(2+) release in close conjunction with two accessory proteins, triadin and junctin. Based on data from cardiomyocytes, we hypothesized that enhanced triadin expression could cause VT. We assessed arrhythmias and electrophysiological changes in vivo and in the beating heart in mice expressing junctin, triadin, or both proteins (TRDxJCN), and measured calcium transients in isolated ventricular cardiomyocytes. TRDxJCN mice were studied to compensate the down-regulation of junctin expression in triadin-expressing mice. Exercise or stress provoked repetitive VT in freely roaming TRDxJCN mice whenever heart rate increased above approximately 600 bpm (p<0.05 vs. the three other genotypes). TRDxJCN mice expressed total triadin 2.9-fold (p<0.05) and total junctin not different to wildtype (p=ns). Left ventricular systolic function was not different between lineages. beta-adrenoreceptor stimulation (orciprenaline 1.7 microM) provoked early-coupled ventricular ectopy and repetitive VT in isolated, Langendorff-perfused TRDxJCN hearts (p<0.05). Under conditions associated with VT (high pacing rate, catecholamine stimulation), action potential duration was shorter in TRDxJCN with VT than in the other genotypes and shorter than in TRDxJCN hearts without VT (p<0.05). Ca(2+) transient duration was prolonged in Indo1-loaded TRDxJCN cardiomyocytes under VT-provoking conditions. Action potential prolongation by mexiletine (2 microM or 4 microM) or clarithromycine (150 microM) suppressed VT. Expression of triadin provokes stress- and tachycardia-related ventricular arrhythmias in mice. An imbalance between prolonged intracellular calcium release and shortening of the ventricular action potential may contribute to genesis of arrhythmias in this model.
Collapse
Affiliation(s)
- Paulus Kirchhof
- Department of Cardiology and Angiology, Hospital of the University of Münster, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Yuan Q, Fan GC, Dong M, Altschafl B, Diwan A, Ren X, Hahn HH, Zhao W, Waggoner JR, Jones LR, Jones WK, Bers DM, Dorn GW, Wang HS, Valdivia HH, Chu G, Kranias EG. Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility but increases ventricular automaticity. Circulation 2007; 115:300-9. [PMID: 17224479 DOI: 10.1161/circulationaha.106.654699] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Abnormal sarcoplasmic reticulum calcium (Ca) cycling is increasingly recognized as an important mechanism for increased ventricular automaticity that leads to lethal ventricular arrhythmias. Previous studies have linked lethal familial arrhythmogenic disorders to mutations in the ryanodine receptor and calsequestrin genes, which interact with junctin and triadin to form a macromolecular Ca-signaling complex. The essential physiological effects of junctin and its potential regulatory roles in sarcoplasmic reticulum Ca cycling and Ca-dependent cardiac functions, such as myocyte contractility and automaticity, are unknown. METHODS AND RESULTS The junctin gene was targeted in embryonic stem cells, and a junctin-deficient mouse was generated. Ablation of junctin was associated with enhanced cardiac function in vivo, and junctin-deficient cardiomyocytes exhibited increased contractile and Ca-cycling parameters. Short-term isoproterenol stimulation elicited arrhythmias, including premature ventricular contractions, atrioventricular heart block, and ventricular tachycardia. Long-term isoproterenol infusion also induced premature ventricular contractions and atrioventricular heart block in junctin-null mice. Further examination of the electrical activity revealed a significant increase in the occurrence of delayed afterdepolarizations. Consistently, 25% of the junctin-null mice died by 3 months of age with structurally normal hearts. CONCLUSIONS Junctin is an essential regulator of sarcoplasmic reticulum Ca release and contractility in normal hearts. Ablation of junctin is associated with aberrant Ca homeostasis, which leads to fatal arrhythmias. Thus, normal intracellular Ca cycling relies on maintenance of junctin levels and an intricate balance among the components in the sarcoplasmic reticulum quaternary Ca-signaling complex.
Collapse
Affiliation(s)
- Qunying Yuan
- Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0575, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
McCarron JG, Chalmers S, Bradley KN, MacMillan D, Muir TC. Ca2+ microdomains in smooth muscle. Cell Calcium 2006; 40:461-93. [PMID: 17069885 DOI: 10.1016/j.ceca.2006.08.010] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2006] [Accepted: 08/23/2006] [Indexed: 02/03/2023]
Abstract
In smooth muscle, Ca(2+) controls diverse activities including cell division, contraction and cell death. Of particular significance in enabling Ca(2+) to perform these multiple functions is the cell's ability to localize Ca(2+) signals to certain regions by creating high local concentrations of Ca(2+) (microdomains), which differ from the cytoplasmic average. Microdomains arise from Ca(2+) influx across the plasma membrane or release from the sarcoplasmic reticulum (SR) Ca(2+) store. A single Ca(2+) channel can create a microdomain of several micromolar near (approximately 200 nm) the channel. This concentration declines quickly with peak rates of several thousand micromolar per second when influx ends. The high [Ca(2+)] and the rapid rates of decline target Ca(2+) signals to effectors in the microdomain with rapid kinetics and enable the selective activation of cellular processes. Several elements within the cell combine to enable microdomains to develop. These include the brief open time of ion channels, localization of Ca(2+) by buffering, the clustering of ion channels to certain regions of the cell and the presence of membrane barriers, which restrict the free diffusion of Ca(2+). In this review, the generation of microdomains arising from Ca(2+) influx across the plasma membrane and the release of the ion from the SR Ca(2+) store will be discussed and the contribution of mitochondria and the Golgi apparatus as well as endogenous modulators (e.g. cADPR and channel binding proteins) will be considered.
Collapse
Affiliation(s)
- John G McCarron
- Department of Physiology and Pharmacology, University of Strathclyde, SIPBS, Glasgow, UK.
| | | | | | | | | |
Collapse
|